Perioperative Therapy for Borderline Resectable Pancreatic Cancer: What and When?

Ann Surg Oncol. 2019 Jun;26(6):1596-1597. doi: 10.1245/s10434-019-07177-2. Epub 2019 Jan 24.

Authors

Michael P Kim¹, Matthew H G Katz²

Affiliations

¹ Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
² Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. mhgkatz@mdanderson.org.

PMID: 30680479
DOI: 10.1245/s10434-019-07177-2

No abstract available

Publication types

Editorial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Humans
Neoadjuvant Therapy / mortality*
Pancreatectomy / mortality*
Pancreatic Neoplasms / drug therapy*
Pancreatic Neoplasms / pathology
Pancreatic Neoplasms / surgery
Perioperative Care / mortality*
Prognosis
Survival Rate